Informationen:
Fehler:
ID
43681
Beschreibung
Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab; ODM derived from: https://clinicaltrials.gov/show/NCT02236806
Link
https://clinicaltrials.gov/show/NCT02236806
Stichworte
Versionen (2)
- 26.04.16 26.04.16 -
- 20.09.21 20.09.21 -
Hochgeladen am
20. September 2021
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Breast Cancer NCT02236806
Eligibility Breast Cancer NCT02236806
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Breast Cancer NCT02236806
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Female
Item
female
boolean
C0086287 (UMLS CUI [1])
Age
Item
age >18 years
boolean
C0001779 (UMLS CUI [1])
Invasive breast carcinoma Histologic Confirmed
Item
non-metastatic histologically confirmed primary invasive breast cancer
boolean
C0853879 (UMLS CUI [1,1])
C0205462 (UMLS CUI [1,2])
C0521093 (UMLS CUI [1,3])
C0205462 (UMLS CUI [1,2])
C0521093 (UMLS CUI [1,3])
Anthracycline Antibiotics Neoadjuvant Therapy | Anthracycline Antibiotics Adjuvant therapy | Human Epidermal Growth Factor Receptor 2 Measurement Monoclonal Antibodies Therapeutic procedure
Item
scheduled to receive neoadjuvant and/or adjuvant anthracyclines with or without anti-her2 therapy
boolean
C0003234 (UMLS CUI [1,1])
C0600558 (UMLS CUI [1,2])
C0003234 (UMLS CUI [2,1])
C0677850 (UMLS CUI [2,2])
C3810543 (UMLS CUI [3,1])
C0003250 (UMLS CUI [3,2])
C0087111 (UMLS CUI [3,3])
C0600558 (UMLS CUI [1,2])
C0003234 (UMLS CUI [2,1])
C0677850 (UMLS CUI [2,2])
C3810543 (UMLS CUI [3,1])
C0003250 (UMLS CUI [3,2])
C0087111 (UMLS CUI [3,3])
Informed Consent
Item
provided informed consent
boolean
C0021430 (UMLS CUI [1])
Able to swallow capsule
Item
able to swallow capsules
boolean
C2712086 (UMLS CUI [1,1])
C0006935 (UMLS CUI [1,2])
C0006935 (UMLS CUI [1,2])
Left ventricular ejection fraction
Item
lvef > 50%
boolean
C0428772 (UMLS CUI [1])
Pregnancy | Breast Feeding
Item
pregnant or lactating women
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
Treated with Angiotensin-Converting Enzyme Inhibitors | Treated with Adrenergic beta-Antagonists
Item
treatment with ace-inhibitors or beta blockers at diagnosis
boolean
C0332293 (UMLS CUI [1,1])
C0003015 (UMLS CUI [1,2])
C0332293 (UMLS CUI [2,1])
C0001645 (UMLS CUI [2,2])
C0003015 (UMLS CUI [1,2])
C0332293 (UMLS CUI [2,1])
C0001645 (UMLS CUI [2,2])
Common Terminology Criteria for Adverse Events | Congestive heart failure | Myocardial infarction | Left ventricular ejection fraction Dysfunction | Valvular disease | Cardiac Arrhythmia
Item
history of nci common toxicity criteria for adverse effects (ctcae) (version 4.0) grade >2 symptomatic congestive heart failure (chf), previous myocardial infarction, significant symptoms (grade>2) relating to lvef dysfunction, valvular disease, cardiac arrhythmia (grade>3)
boolean
C1516728 (UMLS CUI [1])
C0018802 (UMLS CUI [2])
C0027051 (UMLS CUI [3])
C0428772 (UMLS CUI [4,1])
C3887504 (UMLS CUI [4,2])
C3258293 (UMLS CUI [5])
C0003811 (UMLS CUI [6])
C0018802 (UMLS CUI [2])
C0027051 (UMLS CUI [3])
C0428772 (UMLS CUI [4,1])
C3887504 (UMLS CUI [4,2])
C3258293 (UMLS CUI [5])
C0003811 (UMLS CUI [6])